What happened with INBS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Intelligent Bio Solutions Inc. supplies employers in safety-critical industries, such as construction and transportation, as well as drug-treatment and judicial organizations. Its Intelligent Fingerprinting Drug Screening System collects fingerprint sweat on a disposable cartridge and uses a portable reader to screen for drugs, without collecting urine, saliva or blood. Samples requiring confirmation can be sent to a third-party laboratory.
Customers buy readers and then purchase fresh cartridges for further tests. Cartridges account for most revenue, so the business depends on customers continuing to use the installed readers. The company sells directly and through distributors that buy products for resale. Almost all revenue comes from the United Kingdom.
Product sales remain insufficient to cover operating costs, and the company needs additional financing. Confirmation testing depends on a small group of laboratory providers with few alternatives. The system has not received U.S. regulatory approval; apart from limited forensic-use-only sales, sales are outside the United States. Entering additional markets depends on obtaining the required regulatory clearances or approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Intelligent Bio Solutions Inc.’s results hinge on UK workplaces adopting its drug screening and buying replacement cartridges, with Syrma Johari MedTech supplying readers to support production scale and margins.
Intelligent Bio Solutions Inc. earningsThis company
Intelligent Bio Solutions sells fingerprint drug-screening readers and single-use cartridges, and this report will show whether reader sales are building repeat cartridge revenue.
Read reader sales alongside cartridge sales. If cartridges grow with readers, new placements and existing customers are both supporting repeat consumables revenue. If readers grow but cartridges do not keep pace, the larger reader base is not yet translating into consumables revenue at the same rate. That shows whether the company's reader-and-cartridge model is taking hold.
